Comparison
6q16 Deletion Syndrome C5438727 vs 6 Phosphogluconate Dehydrogenase Deficiency C5543091
Clinical comparison between 6q16 Deletion Syndrome and 6 Phosphogluconate Dehydrogenase Deficiency for differential diagnosis and treatment planning.
6q16 Deletion Syndrome C5438727
A rare disorder caused by deletion of genetic material from chromosome 6. This primarily affects brain development and may cause developmental delays, behavioral differences, and distinctive facial features. Care involves multidisciplinary support.
6 Phosphogluconate Dehydrogenase Deficiency C5543091
A rare enzyme deficiency affecting red blood cells that can cause anemia during oxidative stress. Symptoms may flare with certain medications or infections. Managed with avoidance of triggers.
6 comparison axes
Onset
6q16 Deletion Syndrome C5438727
Variable
6 Phosphogluconate Dehydrogenase Deficiency C5543091
Variable
Onset patterns differ
Severity
6q16 Deletion Syndrome C5438727
moderate
6 Phosphogluconate Dehydrogenase Deficiency C5543091
mild
Different severity levels
Chronic
6q16 Deletion Syndrome C5438727
Chronic
6 Phosphogluconate Dehydrogenase Deficiency C5543091
Chronic
Differing course
Communicable
6q16 Deletion Syndrome C5438727
No
6 Phosphogluconate Dehydrogenase Deficiency C5543091
No
Different transmission
Body System
6q16 Deletion Syndrome C5438727
congenital
6 Phosphogluconate Dehydrogenase Deficiency C5543091
metabolic
Same/different system
Category
6q16 Deletion Syndrome C5438727
genetic
6 Phosphogluconate Dehydrogenase Deficiency C5543091
metabolic
Different category
Bottom line
6q16-deletion-syndrome-C5438727 and 6-phosphogluconate-dehydrogenase-deficiency-C5543091 differ in severity, etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | 6q16 Deletion Syndrome C5438727 | 6 Phosphogluconate Dehydrogenase Deficiency C5543091 | Discriminating power |
|---|---|---|---|
| Developmental delay | May be a core feature from early life, with learning or behavioral differences. | Not a typical feature based on the supplied description. | High |
| Anemia during stress | Not described as the primary presentation. | May occur during oxidative stress, infection, or certain medicines. | High |
| Facial features | Distinctive facial features may be present but are not diagnostic alone. | No characteristic facial pattern is established in the source data. | Moderate |
When to favor each condition
Choose 6q16 Deletion Syndrome C5438727 when
Congenital developmental concerns
A chromosomal deletion better fits early neurodevelopmental findings.
Moderate
Suspected copy-number variant
Genetic testing is the appropriate route when a deletion is suspected.
High
Need for developmental support
Care is multidisciplinary rather than trigger avoidance alone.
Moderate
Choose 6 Phosphogluconate Dehydrogenase Deficiency C5543091 when
Hemolysis after a trigger
An enzyme-related red-cell disorder fits episodic anemia better.
Moderate
Medicine or infection flare
The source links symptoms to oxidative stress, medicines, or infection.
Moderate
Metabolic enzyme evaluation
Enzyme testing is relevant when this deficiency is specifically suspected.
High
How key tests differ
| Test | 6q16 Deletion Syndrome C5438727 | 6 Phosphogluconate Dehydrogenase Deficiency C5543091 | Interpretation |
|---|---|---|---|
| Chromosomal microarray | May identify a 6q16 deletion if present. | Not expected to diagnose this enzyme deficiency. | A deletion supports the chromosomal condition; absence needs clinician review. |
| Enzyme assay | Not the primary confirmatory test. | May show reduced 6-phosphogluconate dehydrogenase activity. | Interpret with the laboratory method; no cutoff is supplied here. |
| Hemolysis studies | No characteristic hemolysis pattern is established. | May suggest red-cell breakdown during a symptomatic episode. | Abnormal results are findings, not a diagnosis by themselves. |
Prognosis comparison
6q16 Deletion Syndrome C5438727
- Outcome
- Often a chronic developmental condition; individual outcome is not established here.
- Factors
- Deletion extent, associated findings, and available support may influence needs.
6 Phosphogluconate Dehydrogenase Deficiency C5543091
- Outcome
- Often described as mild, with possible episodic anemia; long-term outcome is not established.
- Factors
- Exposure to oxidative triggers, infections, and prompt recognition may matter.
Time frame: Both may be lifelong, but course and severity vary.
Prognosis should be interpreted by clinicians using the full genetic or laboratory result.
Complications comparison
| Complication | Presentation |
|---|---|
| Learning and behavior needs | Developmental and behavioral support needs may persist. Not established as a typical complication. Needs vary; source data do not define severity. |
| Episodic anemia | Not described as characteristic. May occur with oxidative stress and require clinical assessment. Exact frequency and severity are not established. |
| Trigger-related illness | No specific medicine or infection trigger is established. Symptoms may flare with selected medicines or infections. Trigger lists should come from the treating clinician. |
Patient education highlights
- HighDifferent conditions
Similar names do not mean the same disease; one is chromosomal and one is enzymatic.
- HighWhen to seek care
Seek urgent care for severe weakness, pallor, jaundice, breathing trouble, or sudden illness.
- MediumIndividual plan
Management, monitoring, and restrictions should be individualized by a clinician.